Topical Janus Kinase Inhibitors
Customize your policy alerts
Sign up for allcareadvantage Policy 135.1 alerts
Get alerted when Policy 135.1 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and coverage criteria for topical JAK inhibitor therapies (delgocitinib, ruxolitinib) for treatment of chronic hand eczema in adult AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Topical JAK Inhibitors
Initial and Renewal Therapy
Covered when ALL of the following are met:
If all met, approve up to 6 months; quantity limited to up to maximum FDA daily dose.
If met, approve up to 12 months.
Coverage for topical Janus kinase (JAK) inhibitors is limited to adults and to the FDA‑approved indication: topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. This policy applies to the specified agents (Anzupgo [delgocitinib] and Opzelura [ruxolitinib]) and requires documentation that the request matches the approved indication.
Use of topical JAK inhibitors is considered not medically necessary when the documented criteria are not met. Examples include: member age <18 years; diagnosis that does not match the FDA‑approved indication of moderate to severe chronic hand eczema; medication not prescribed by or in consultation with a dermatologist; or inadequate documentation of prior trials/failures or contraindications to emollients and other required therapies. Requests lacking required renewal documentation of clinical benefit (eg, improvement in severity or activities of daily living compared to baseline) will also be denied.
Initial Therapy Requirements
Initial Therapy
Initial authorization decision logic
If met, approve up to 6 months; quantity limited to up to maximum FDA daily dose.
| Step | Required prior therapies (trial and fail or contraindication) | Coverage action |
|---|---|---|
| 1 | ||
| Emollient therapy (adequate trial) — documentation of failure or contraindication required | ||
| Must meet requirement — approval contingent on documented failure or contraindication |
Renewal / Continuation Requirements
Renewal
Renewal requirements for continuation of topical JAK inhibitor therapy.
If met, approve up to 12 months.
Prior Authorization and Documentation Requirements
Prior authorization required and review follows stepwise criteria
Prior authorization is required for topical JAK inhibitors; review follows the stepwise criteria in the policy including patient age (must be ≥18), documentation of a diagnosis consistent with the FDA‑approved indication (moderate to severe chronic hand eczema), that the medication is prescribed by or in consultation with a dermatologist, and demonstration of required prior therapy trials/failures or contraindications. If all initial criteria are met the policy allows approval up to 6 months (renewal up to 12 months).
- Initial approval: up to 6 months; Renewal: up to 12 months
- Quantity limited to up to maximum FDA daily dose
Documented failure or contraindication to emollients and other therapies required
Approval requires documented failure of, or contraindication to, an adequate trial of emollient therapy and documented failure of or contraindication to other recommended/formulary therapies (for example high‑potency/super‑high‑potency topical corticosteroids, topical tacrolimus, phototherapy, or oral immunosuppressants) before topical JAK inhibitors will be approved.
- Must document failure or contraindication to emollients (Criteria #6)
- Must document failure or contraindication to other recommended/formulary therapies (Criteria #7)
Submit supporting clinical documentation and renewal evidence
Provider must submit chart documentation that supports an FDA‑approved diagnosis (moderate to severe chronic hand eczema), prior trials and failures or contraindications to emollient therapy and other recommended/formulary therapies, and for renewals evidence of clinical efficacy (for example reduction in severity or improved activities of daily living compared to baseline).
- Documentation supporting diagnosis consistent with FDA‑approved indication (Criteria #3)
- Documentation of trials/failures or contraindications to emollients (Criteria #6) and other therapies (Criteria #7)
- For renewals, chart notes demonstrating clinical efficacy (eg, reduction in severity or improvement in ADLs)
Denial risks: age, indication, prescriber specialty, and insufficient documentation
Denial will be issued if the member is under 18, the submitted diagnosis does not match the FDA‑approved indication, the medication is not prescribed by or in consultation with a dermatologist, or required documentation of prior therapy failure/contraindication or renewal clinical benefit is insufficient.
- Member age <18 (Criteria #2) — does not meet criteria
- Diagnosis not consistent with FDA‑approved indication (Criteria #3) — deny
- Medication not prescribed by or in consultation with a dermatologist (Criteria #4) — deny
- Insufficient documentation of failure/contraindication to emollients or other required therapies (Criteria #6/#7) — deny
- For renewals, lack of documentation demonstrating clinical efficacy — deny
Quantity and Dosing Limits
Definitions and Background
Chronic hand eczema (CHE) is managed first‑line with liberal use of emollients and, for active flares, high‑ or super high‑potency topical corticosteroids (groups 1–3). Topical tacrolimus may be used as a steroid‑sparing option or when contact allergy to topical corticosteroids is present. For severe or recalcitrant disease, options include short courses of oral corticosteroids, phototherapy, oral immunosuppressants (eg, methotrexate, cyclosporin, azathioprine), or biologics (eg, dupilumab for atopic CHE). Topical JAK inhibitors (delgocitinib, ruxolitinib) are considered for patients who have failed or cannot use topical corticosteroids and other recommended therapies, and their use should be reserved for patients with prior treatment failure or contraindications to those alternatives.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.